Article Text

PDF
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis
  1. Lennart T H Jacobsson1,
  2. Carl Turesson1,
  3. Jan-Åke Nilsson1,
  4. Ingemar F Petersson2,
  5. Elisabet Lindqvist3,
  6. Tore Saxne3,
  7. Pierre Geborek3
  1. 1Department of Rheumatology, Malmö University Hospital, Malmö, Sweden
  2. 2Spenshult Hospital for Rheumatic Diseases, Halmstad, Sweden
  3. 3Department of Rheumatology, Lund University Hospital, Lund, Sweden
  1. Correspondence to:
    Dr L T H Jacobsson
    Department of Rheumatology, Malmö University Hospital, S-205 02 Malmö, Sweden; lennart.jacobsson{at}medforsk.mas.lu.se

Abstract

Objective: To assess mortality in patients with rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) inhibitors, compared with a standard RA population.

Methods: Patients were recruited from a regional register, which includes over 90% of patients with RA treated with TNF blockers in the area in 1999 or later, and a local community-based cohort of patients with RA, established in 1997. Of a total of 1430 patients in the combined cohort <80 years old, 921 received treatment with TNF inhibitors during the study period. The total cohort was linked with the national register for cause of death. Overall mortality in those treated versus those not treated with TNF blockers was estimated using standardised mortality ratios and time-dependent Cox proportional hazards.

Results: There were 188 deaths per 7077 person-years at risk in the total cohort. Controlling for age, sex, disability and baseline comorbidity, the adjusted HR for death was 0.65 (95% CI 0.46 to 0.93) in those treated with anti-TNF versus those not treated. The effect was significant in women (HR = 0.52, 95% CI 0.33 to 0.82) but not in men (HR = 0.95, 95% CI 0.52 to 1.71).

Conclusion: After adjusting for disease severity, treatment with TNF inhibitors was found to be associated with a reduced mortality in women but not men with RA. These findings are compatible with a critical role for inflammation in RA-associated premature mortality.

  • COPD, chronic obstructive pulmonary disease
  • CVD, cardiovascular disease
  • DMARD, disease-modifying antirheumatic drug
  • HAQ, Health Assessment Questionnaire
  • ICD, International Classification of Diseases
  • PYRS, person-years
  • RA, rheumatoid arthritis
  • SMR, standardised mortality ratio
  • SSATG, South Swedish Arthritis Treatment Group
  • TNF, tumour necrosis factor
  • VAS, visual analogue scale

Statistics from Altmetric.com

Footnotes

  • Published Online First 11 December 2006

  • Funding: This work was supported by grants from The Swedish Medical Research Council, King Gustaf V 80-year Foundation, The Swedish Rheumatism Association, and the Österlund and the Kock Foundations.

  • Competing interests: None.

  • Ethical approval: This study was approved by the research ethics committee at Lund University, Lund, Sweden.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.